Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0RB6L
|
|||
| Drug Name |
rhACE2
|
|||
| Synonyms |
recombinant human ACE2; APN01
Click to Show/Hide
|
|||
| Drug Type |
Protein/peptide drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN angiotensin-converting enzyme 2 (ACE2) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04335136) Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04287686) Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.